Analysts Have Conflicting Sentiments on These Industrial Goods Companies: Redwire (RDW) and CryoPort (CYRX)
This article analyzes recent analyst ratings for two industrial goods companies, Redwire (RDW) and CryoPort (CYRX). KeyBanc maintained a Hold rating on Redwire, while CryoPort received a Buy rating from KeyBanc and an upgrade to Buy from TipRanks – PerPlexity. The consensus on Redwire is a Moderate Buy, and CryoPort holds a Strong Buy consensus.
KeyBanc raises CryoPort stock price target to $17 on growth outlook
KeyBanc has increased its price target for CryoPort (NASDAQ:CYRX) stock to $17 from $15, reiterating an Overweight rating due to improved revenue visibility, better quality growth than the COVID era, and projected margin expansion through 2028. The company's stock has seen significant growth, surging 93% over the past year. Despite a perceived overvaluation according to InvestingPro data, other analysts like Needham and BTIG also raised their price targets after CryoPort's Q1 2026 earnings beat revenue expectations, although it reported a larger-than-expected loss per share.
Understanding Momentum Shifts in (CYRX)
This article analyzes momentum shifts for Cryoport Inc. (NASDAQ: CYRX), indicating a near-term neutral sentiment amidst mid and long-term strength. It identifies elevated downside risk and provides three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Cryoport Inc stock (US2289031005): earnings update keeps focus on biotech logistics growth
Cryoport Inc, a specialist in temperature-controlled logistics for the life sciences industry, reported its latest quarterly earnings, highlighting growth opportunities and execution challenges. The company focuses on providing temperature-controlled supply chain solutions for cell and gene therapy, reproductive medicine, and biopharma research, operating globally with strong ties to North America, Europe, and Asia. For US investors, Cryoport offers exposure to the advanced therapies market without direct drug development risk, leveraging its Nasdaq listing and USD reporting, though it remains sensitive to biotech sector cycles and investment needs.
Cryoport Powers Cell Therapy Boom, Eyes Profitability Amid Record Growth
Cryoport, a key player in the ultra-cold supply chain for cell and gene therapies, reported robust financial results for 2025 with $176.2 million in revenue, a 12% increase from the previous year. The company is actively solidifying its market leadership, supporting 760 global clinical trials, and showing significant progress towards profitability after divesting its specialty courier business and focusing on its high-margin life sciences services. Cryoport is also investing heavily in infrastructure and innovation to maintain its competitive edge in the rapidly expanding cell and gene therapy logistics market.
Cryoport Inc stock (US2289031005): Q1 revenue beats estimates in volatile cell and gene logistics market
Cryoport Inc (CYRX) reported Q1 2026 revenue that exceeded analyst estimates, despite continued net losses, navigating a volatile market for cell and gene therapy logistics. The company specializes in temperature-controlled logistics and biostorage, positioning itself as an infrastructure partner for the advanced therapies sector. Its performance reflects strong demand in core service lines amidst growth investments and cost pressures.
Cryoport Inc stock (US2289031005): Short interest drops to 4.86% as of April 30
Cryoport Inc saw its short interest drop to 4.86% of its float as of April 30, 2026, indicating reduced bearish sentiment for the temperature-controlled logistics provider. This decline suggests easing pressure from short sellers in the biotech supply chain sector. The company specializes in cryogenic logistics for the life sciences industry, supporting cell and gene therapy clinical trials, and offers US investors exposure to this growing market.
Number of shareholders of CryoPort, Inc. – NASDAQ:CYRX
This page provides information regarding the number of shareholders of CryoPort, Inc. (NASDAQ: CYRX). It details various financial and stock market information for the company, accessible through TradingView. The content also briefly mentions the company's market and financial data sources.
CryoPort (NASDAQ:CYRX) Upgraded at Wall Street Zen
CryoPort (NASDAQ:CYRX) was upgraded from a "sell" to a "hold" rating by Wall Street Zen. This upgrade, along with positive revisions from other firms, contributes to a 'Moderate Buy' average analyst rating and a $14.44 average price target. Despite reporting revenue of $47.8 million, exceeding estimates, the company missed EPS expectations at -$0.23.
Cryoport projects $192M-$196M FY 2026 revenue and expects positive adjusted EBITDA in 2H 2026
Cryoport (NASDAQ:CYRX) has provided its financial outlook for fiscal year 2026, anticipating revenues between $192 million and $196 million. The company also projects achieving positive adjusted EBITDA during the second half of 2026. This announcement gives investors insight into Cryoport's future financial performance and profitability expectations.
Analysts Conflicted on These Industrial Goods Names: CryoPort (CYRX) and Thomson Reuters (TRI)
Analysts are divided on two Industrial Goods companies, CryoPort (CYRX) and Thomson Reuters (TRI). Roth MKM maintains a Buy rating on CryoPort with a $15.00 price target, while Wells Fargo holds a Hold rating on Thomson Reuters. CryoPort has a "Strong Buy" consensus, whereas Thomson Reuters also has a "Strong Buy" consensus despite the Hold rating from Wells Fargo.
Cryoport Is Maintained at Buy by Guggenheim
Guggenheim has reiterated its Buy rating on Cryoport (NASDAQ: CYRX) stock. The analyst believes Cryoport's current market position warrants the continued positive outlook.
CryoPort, Inc. (CYRX) reports Q1 loss, tops revenue estimates
CryoPort, Inc. (CYRX) reported a loss of $0.47 per share for the first quarter, which is wider than the Zacks Consensus Estimate. However, the company surpassed revenue estimates, posting $61.76 million against an expected $60.6 million.
Cryoport, Inc. 1Q 2026: Revenue $47.8M, EPS ($0.25) — 10-Q Summary
Cryoport, Inc. reported its first-quarter 2026 results, showing a 16.5% year-over-year revenue increase to $47.8 million, with diluted loss per share improving to ($0.25). The company saw broad-based revenue growth across services and products, supported 766 clinical trials, and completed a strategic divestiture of CRYOPDP to DHL for expanded capabilities. Cryoport also continued operational investments in site expansions, new equipment, and digital enhancements.
CryoPort (NASDAQ:CYRX) Hits New 12-Month High on Analyst Upgrade
CryoPort (NASDAQ:CYRX) shares reached a new 52-week high after Guggenheim raised its price target and several analysts issued "buy" ratings, leading to a "Moderate Buy" consensus. The company's Q1 revenue of $47.8M surpassed estimates, and FY-2026 revenue guidance was raised to $192-$196M, driven by strong growth in cell & gene therapy and life sciences. Despite these positive indicators, CryoPort missed EPS estimates and remains GAAP loss-making, with recent insider stock sales, making its valuation dependent on sustained revenue growth.
Cryoport Posts Revenue Beat In Q1 As Clinical Trial Support Hits All-Time High — 'A Strong Start To 2026'
Cryoport Inc. (NASDAQ: CYRX) exceeded Q1 revenue estimates with $47.8 million, driven by strong growth in Life Sciences Services and Products, despite reporting a net loss of 25 cents per share. The company supported a record 766 global clinical trials and raised its full-year revenue outlook to $192 million–$196 million, with management anticipating continued momentum and progress towards profitability.
CryoPort (NASDAQ:CYRX) Shares Gap Up on Analyst Upgrade
CryoPort (NASDAQ:CYRX) shares gapped up after multiple analysts upgraded the stock and raised price targets, including Guggenheim. This positive sentiment follows the company's Q1 revenue beat and increased FY2026 revenue guidance, despite missing EPS expectations and remaining unprofitable. The article also notes significant institutional ownership and recent insider selling.
Cryoport, Inc. (NASDAQ:CYRX) Q1 2026 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX) reported strong Q1 2026 results, with revenue up 16% year-over-year to $47.8 million, driven by growth in both Life Sciences Services and Products segments. The company raised its full-year 2026 revenue guidance to $192 million to $196 million and anticipates achieving positive adjusted EBITDA in the second half of the year. Cryoport continues to expand its support for commercial cell and gene therapies, now aiding 21 therapies, and saw significant growth in both commercial and clinical trial revenue.
Needham raises CryoPort stock price target to $15 on revenue beat
Needham has increased its price target for CryoPort (NASDAQ:CYRX) shares to $15 from $13, maintaining a Buy rating, following the company's strong first-quarter fiscal 2026 revenue results which surpassed consensus estimates. The company also raised its full-year revenue guidance for fiscal 2026. This positive outlook is supported by broad-based strength in both services and products, with management targeting adjusted EBITDA profitability in the second half of fiscal 2026.
Cryoport projects $192M-$196M FY 2026 revenue and expects positive adjusted EBITDA in 2H 2026
Cryoport (CYRX) announced its financial outlook for fiscal year 2026, projecting revenues between $192 million and $196 million. The company also anticipates achieving positive adjusted EBITDA in the second half of 2026. This forecast provides insights into Cryoport's expected financial performance and its path to profitability.
Cryoport, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:CYRX) 2026-05-04
Cryoport, Inc. (NASDAQ:CYRX) released its Q1 2026 earnings, reporting an EPS of -$0.19, which beat expectations by $0.00. The company also announced revenue of $47.80M, marking a 16.47% year-over-year increase and beating estimates by $2.94M. This report is based on the slide deck published in conjunction with their earnings call.
CryoPort (NASDAQ:CYRX) Posts Earnings Results, Misses Expectations By $0.03 EPS
CryoPort (NASDAQ:CYRX) released its quarterly earnings, reporting an EPS of ($0.23), which missed analysts' consensus estimate of ($0.20) by $0.03. Following the announcement, the stock dipped to $10.21 on Monday. Analysts currently rate the stock as a "Moderate Buy" with an average price target of $13.31, despite recent insider selling totaling $471,183.
Cryoport (CYRX) Q1 2026 Earnings Transcript
Cryoport (CYRX) reported a strong Q1 2026, with total revenue increasing 16% year over year to $47.8 million, driven by growth in integrated services and products. The company raised its full-year 2026 revenue guidance to $192 million to $196 million and expects to achieve positive adjusted EBITDA in the second half of the year. Cryoport is expanding its service offerings, supporting a record 766 global clinical trials, and leveraging AI and facility expansions to drive operational efficiencies and future growth.
Cryoport reports Q1 2026 revenue up 16% to $47.8M, raises full-year guidance
Cryoport reported a 16% year-over-year revenue increase to $47.8 million in Q1 2026, leading to a raised full-year guidance of $192 million–$196 million. Despite a net loss, the company saw significant growth in its commercial cell and gene therapy revenue, life sciences services, and products, alongside expanding its operational footprint. Cryoport is also supporting a record number of global clinical trials.
Cryoport Posts Revenue Beat In Q1 As Clinical Trial Support Hits All-Time High — 'A Strong Start To 2026'
Cryoport (NASDAQ: CYRX) reported beating Q1 revenue estimates with $47.8 million, driven by 16% year-over-year growth in its Life Sciences segments and a record 766 clinical trials supported. Despite a net loss, the company raised its full-year revenue outlook to $192 million–$196 million and highlighted progress towards profitability, with upcoming Global Supply Chain Center launches. Shares closed down 1.35% following the report.
CryoPort Q1 2026 earnings preview
This article provides a preview of CryoPort's Q1 2026 earnings. It is a brief, placeholder article from MSN, indicating future financial reporting.
Cryoport Inc expected to post a loss of 22 cents a share - Earnings Preview
Cryoport Inc (CYRX) is projected to report a loss of 22 cents per share, according to a Refinitiv earnings preview. This financial outlook provides insight into the company's expected performance ahead of its official earnings release.
Discipline and Rules-Based Execution in CYRX Response
This article provides a detailed analysis of Cryoport Inc. (NASDAQ: CYRX) based on AI models, highlighting weak near-term sentiment but strong mid and long-term signals. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and emphasizes an exceptional risk-reward setup.
CryoPort, Inc. (CYRX) reports Q4 loss, tops revenue estimates
CryoPort, Inc. (CYRX) reported a loss for the fourth quarter but exceeded revenue estimates. This indicates a mixed financial performance, with the company growing its top-line revenue faster than anticipated, despite a net loss.
Craig-Hallum initiates coverage of Cryoport (CYRX) with buy recommendation
Craig-Hallum has initiated coverage of Cryoport (CYRX) with a buy recommendation. This signals a positive outlook from the investment bank for the company.
CryoPort (NASDAQ:CYRX) Stock Passes Above 200-Day Moving Average - Time to Sell?
CryoPort (NASDAQ:CYRX) stock recently crossed above its 200-day moving average, trading at $10.59. Despite a "Moderate Buy" consensus rating from analysts with an average target of $13.31, the company missed its recent quarterly EPS estimates. Insider selling of approximately 59,939 shares ($471k) in the last 90 days suggests some internal concerns.
CryoPort (NASDAQ:CYRX) Upgraded at Wall Street Zen
CryoPort (NASDAQ:CYRX) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. The company reported quarterly earnings per share of ($0.21), missing estimates, but revenue beat expectations at $45.45 million. The stock currently holds a "Moderate Buy" consensus rating from analysts with a target price of $13.31.
CYRX Price Today: CryoPort, Inc. Stock Price, Quote & Chart | MEXC
This article provides detailed real-time stock information for CryoPort, Inc. (CYRX), including its current price ($10.59), market capitalization, daily trading data, and historical performance. It also offers a guide on how to buy CYRX shares on MEXC and provides an overview of the company's business in the life sciences industry, focusing on temperature-controlled supply chain solutions. The content includes an extensive FAQ section covering financial metrics, performance trends, and earnings information.
[Form 4] Cryoport, Inc. Insider Trading Activity
Cryoport, Inc. CEO Jerrell Shelton exercised stock options to acquire 104,007 shares of common stock at $1.87 per share. These options, which vested monthly over four years starting May 6, 2016, were fully exercised, leaving no remaining from this grant. After the transaction, Shelton directly holds 1,230,614 common shares, indicating an exercise-and-hold pattern as no same-day sales were reported.
Cryoport, Inc. SEC Filing
This article reports on a recent ARS SEC filing by Cryoport, Inc. (CYRX) on April 22, 2026, indicating a low impact and neutral sentiment. The filing is available as a PDF document and provides information about the company's financial overview, latest news, and SEC filings. Cryoport is ranked #3469 by market cap and is a monthly gainer.
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
Cryoport, Inc. announced it will release its first quarter 2026 financial results on Monday, May 4, 2026, after U.S. markets close. The company will also publish a "Cryoport First Quarter 2026 in Review" document and host a questions and answers conference call with investors at 5:00 p.m. ET on the same day. Cryoport is a global provider of integrated temperature-controlled supply chain solutions for the life sciences.
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
Cryoport, Inc. announced it will report its first quarter 2026 financial results on Monday, May 4, 2026, after U.S. markets close. The company will also release a "Cryoport First Quarter 2026 in Review" document and host a questions and answers conference call with a slide deck at 5:00 p.m. ET on the same day. This call will address inquiries from the investment community regarding the reported results.
Cryoport schedules May 4 earnings release, 5 p.m. investor Q&A
Cryoport (NASDAQ: CYRX) announced it will report its first-quarter 2026 financial results on Monday, May 4, 2026, after U.S. markets close. Following the earnings release, a "Cryoport First Quarter 2026 in Review" document will be available at 4:05 p.m. ET, and management will host a Q&A conference call at 5:00 p.m. ET. The company will also provide a slide deck and webcast details for investors.
Analysts Offer Insights on Industrial Goods Companies: Ryder System (R) and CryoPort (CYRX)
Morgan Stanley analyst Ravi Shanker maintained a Buy rating on Ryder System (R) with a price target of $263.00, representing a potential upside from its last closing price. Similarly, Craig-Hallum analyst Greg Palm reiterated a Buy rating on CryoPort (CYRX), setting an average price target of $12.75 which suggests a 26.7% upside. Both companies received a Strong Buy consensus rating from analysts.
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
Cryoport, Inc. announced it will report its first quarter results for the period ended March 31, 2026, on Monday, May 4, 2026, after U.S. markets close. The company will also release a document titled "Cryoport First Quarter 2026 in Review" and host a questions and answers conference call with management to discuss the results. Cryoport is a global provider of integrated temperature-controlled supply chain solutions for the life sciences sector.
Cryoport Inc stock (US2289031005): Is its cold chain edge strong enough to unlock new upside?
Cryoport Inc. specializes in temperature-controlled logistics for sensitive biological materials, serving the rapidly growing cell and gene therapy (CGT) market. The company's core business model focuses on precision logistics for life sciences, leveraging specialized technology and a global network to ensure the integrity of high-value shipments. While facing risks like client concentration and capacity constraints, analysts generally maintain positive ratings, emphasizing Cryoport's leadership in CGT, recurring revenue, and long-term growth potential from the booming biotech sector.
CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
CryoPort, Inc. (NASDAQ:CYRX) has received a "Moderate Buy" consensus rating from nine analysts with an average 12-month price target of $13.31. The company recently missed quarterly EPS estimates but exceeded revenue expectations. Insider selling activity was noted, though institutional investors have adjusted their holdings, with 92.90% of the stock owned by institutions.
Behavioral Patterns of CYRX and Institutional Flows
This article analyzes Cryoport Inc. (NASDAQ: CYRX), indicating a strong sentiment across all time horizons and an overweight bias. It highlights a significant 53.0:1 risk-reward setup targeting a 16.0% gain. The piece also provides distinct institutional trading strategies tailored for different risk profiles, including position trading, momentum breakout, and risk hedging strategies.
CYRX Stock Price, Quote & Chart | CRYOPORT INC (NASDAQ:CYRX)
This article provides a detailed overview of CRYOPORT INC (NASDAQ:CYRX) stock, including its current price, performance metrics, key statistics, and technical and fundamental analysis ratings from ChartMill. It also covers recent earnings, analyst forecasts, financial highlights, ownership information, and a company profile outlining its logistics solutions for the life science industry.
Cryoport (CYRX) CEO Jerrell Shelton exercises options, holds 1.13M shares
Cryoport (CYRX) President and CEO Jerrell Shelton exercised stock options for 50,000 shares at an exercise price of $1.87 per share. Following this transaction, he directly holds 1,126,607 shares of Cryoport common stock and 104,007 remaining options. The options exercised were part of a grant that vested monthly over 48 months starting May 6, 2016, and were set to expire on May 6, 2026.
For Cryoport Insiders, Selling US$1.6m Of Shares Was A Smart Move
Insiders at Cryoport (NASDAQ: CYRX) sold US$1.6 million worth of shares over the last year, with Chairman Jerrell Shelton making the largest individual sale. This occurred despite recent stock gains, and the selling price was even below the current market value, suggesting insiders may have viewed a lower price as reasonable. While insiders still collectively own a notable 3.6% of the company, the consistent selling without any purchases raises concerns about their confidence in the stock's future performance.
CYRX PE Ratio & Valuation, Is CYRX Overvalued
This article analyzes the valuation of Cryoport Inc (CYRX), deeming it to be in the "Fair zone" with a fair price range between $4.45 and $28.16 according to relative valuation methods. It highlights that the current forward PS ratio of 2.09 is considered fair compared to its five-year average. The analysis also notes that CYRX's P/S ratio is significantly above the industry average, suggesting that its premium may be unsustainable despite robust revenue growth.
CryoPort (CYRX): New Buy Rating Initiated with $15 Price Target
Craig-Hallum has initiated coverage on CryoPort (CYRX) with a 'Buy' rating and a new price target of $15.00, reflecting analyst Matthew Hewitt's optimism for the company's future. This new rating adds to a history of positive analyst attention for CryoPort, which specializes in temperature-controlled supply chain solutions for the life sciences industry. Wall Street analysts currently project an average target price of $13.33 for CYRX, with an "Outperform" consensus rating.
Craig-Hallum initiates coverage of Cryoport (CYRX) with buy recommendation
Craig-Hallum has initiated coverage of Cryoport (CYRX) with a buy recommendation. This suggests a positive outlook on the company's stock from the investment banking firm.
Craig Hallum Initiates Coverage on CryoPort (NASDAQ:CYRX)
Craig Hallum has initiated coverage on CryoPort (NASDAQ:CYRX) with a "Buy" rating and a $15.00 price target, suggesting an 87% upside. This follows CryoPort's recent financial results, which missed EPS but beat revenue estimates, and mixed analyst ratings including downgrades and price target increases from other firms. Insider selling has occurred recently, though institutional ownership remains high at 92.90%.
